NAGEConsumer Defensive · Packaged FoodsThe 6 Wall Street analysts covering Niagen Bioscience, Inc. hold a median 12-month price target of $11 — +316.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Niagen Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (11): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NAGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +316.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $10 → $9.00 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $11 |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | $13 → $10 |
| 31 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 June 2025 | Roth Capital | Maintains | Buy | — |
| 27 May 2025 | Canaccord Genuity | Initiates | Buy | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2025 | Ladenburg Thalmann | Maintains | Buy | — |
| 6 Nov 2024 | Roth MKM | Maintains | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NAGE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Niagen Bioscience, Inc. returned −63.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 52% of US stocks
Cheaper than 60% of US stocks
Cheaper than 39% of US stocks
Cheaper than 28% of US stocks
Higher than 21% of US stocks
Higher than 6% of US stocks
Higher than 78% of US stocks
Higher than 49% of US stocks
Higher than 74% of US stocks
Higher than 83% of US stocks
Higher than 79% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Niagen Bioscience, Inc. has a market value of $189.9M and an enterprise value of $126.0M.
Revenue in the twelve months to 30 June 2026: $129.1M. The latest quarter shrank 4.3% year on year.
Net income over the same four quarters: $16.0M, a 12.4% net margin.
Diluted earnings per share, trailing twelve months: $0.18.
Free cash flow in the twelve months to 30 June 2026: $5.7M.
Trailing P/E: 12.3×; forward P/E: −38.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Niagen Bioscience, Inc. employs 117 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Niagen Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The headline identifies a Seeking Alpha transcript of Niagen Bioscience, Inc.’s Q3 2026 earnings call; no call details are included in the provided excerpt.
Why it matters — The transcript may be relevant to NAGE watchers, but the excerpt provides no information about the company’s performance or discussion.
Niagen Bioscience reported a third-quarter loss of $0.01 per share, in line with the Zacks Consensus Estimate. That compares with earnings of $0.05 per share a year earlier.
Why it matters — NAGE watchers may note the company moved from year-ago earnings to a quarterly loss, despite matching the consensus estimate.
Niagen Bioscience reported third-quarter 2026 net sales of $27.2 million, including $23.3 million from Tru Niagen. Direct-to-consumer sales on its website increased 13% year over year; the excerpt also reports a gross margin of 62%.
Why it matters — The update provides NAGE watchers with quarterly sales, product revenue, online sales growth, and gross-margin information.
Zacks Investment Research says Niagen Bioscience lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report.
Why it matters — The preview flags expectations for NAGE’s upcoming quarterly earnings report.
Niagen Bioscience announced the launch of its clinician-directed, prescription-only Niagen At-Home Injection Kit, featuring the company’s first ready-to-inject liquid formulation with Niagen (nicotinamide riboside).
Why it matters — The launch adds a liquid at-home injection product to the company’s offerings as it expands telehealth.
The 6 Wall Street analysts covering Niagen Bioscience, Inc. have a median 12-month price target of $11, with estimates ranging from $8.5 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Niagen Bioscience, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Niagen Bioscience, Inc. 55 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Niagen Bioscience, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +316.7% from the last close, and Ticker Nerd's factor model ranks Niagen Bioscience, Inc. 55 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Niagen Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $22 over the next 12 months.
Niagen Bioscience, Inc. returned -63.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript". The headline identifies a Seeking Alpha transcript of Niagen Bioscience, Inc.’s Q3 2026 earnings call; no call details are included in the provided excerpt.
Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science. It develops and commercializes proprietary ingredient technologies and finished dietary supplement products centered on nicotinamide riboside and related NAD+ precursors. The company serves consumer, ingredient, analytical reference standards and services, and pharmaceutical markets through products used in dietary supplements, food and beverage formulations, skin care applications, and research settings. Niagen Bioscience also supplies ingredient raw materials to manufacturers and supports scientific and quality-control work through its analytical and reference standards offerings. Its current portfolio is built around the Niagen platform, which anchors the company’s consumer brands and broader ingredient business, making Niagen Bioscience a specialized participant in the health and wellness, nutraceutical, and bioscience sectors.
CEO Mr. Robert N. Fried · 117 employees · United States · https://www.niagenbioscience.com
